180 related articles for article (PubMed ID: 29807100)
1. Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study.
Vicentini M; Ballotari P; Giorgi Rossi P; Venturelli F; Sacchettini C; Greci M; Mangone L; Pezzarossi A; Manicardi V
Diabetes Res Clin Pract; 2018 Sep; 143():398-408. PubMed ID: 29807100
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy.
Ballotari P; Vicentini M; Manicardi V; Gallo M; Chiatamone Ranieri S; Greci M; Giorgi Rossi P
BMC Cancer; 2017 Oct; 17(1):703. PubMed ID: 29070034
[TBL] [Abstract][Full Text] [Related]
3. Impact of Insulin Therapies on Cancer Incidence in Type 1 and Type 2 Diabetes: A Population-Based Cohort Study in Reggio Emilia, Italy.
Vicentini M; Ballotari P; Venturelli F; Ottone M; Manicardi V; Gallo M; Greci M; Pinotti M; Pezzarossi A; Giorgi Rossi P
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681699
[TBL] [Abstract][Full Text] [Related]
4. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
5. Metformin Treatment and Cancer Risk: Cox Regression Analysis, With Time-Dependent Covariates, of 320,000 Persons With Incident Diabetes Mellitus.
Dankner R; Agay N; Olmer L; Murad H; Keinan Boker L; Balicer RD; Freedman LS
Am J Epidemiol; 2019 Oct; 188(10):1794-1800. PubMed ID: 31269196
[TBL] [Abstract][Full Text] [Related]
6. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
7. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.
Vissers PA; Cardwell CR; van de Poll-Franse LV; Young IS; Pouwer F; Murray LJ
Breast Cancer Res Treat; 2015 Apr; 150(2):427-37. PubMed ID: 25762476
[TBL] [Abstract][Full Text] [Related]
8. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
9. Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK.
Li L; Jick S; Gopalakrishnan C; Heide-Jørgensen U; Nørrelund H; Sørensen HT; Christiansen CF; Ehrenstein V
Diabet Med; 2017 Apr; 34(4):485-489. PubMed ID: 27504911
[TBL] [Abstract][Full Text] [Related]
10. Risk of Cause-Specific Death in Individuals with Cancer-Modifying Role Diabetes, Statins and Metformin.
Haukka J; Niskanen L; Auvinen A
Int J Cancer; 2017 Dec; 141(12):2437-2449. PubMed ID: 28840596
[TBL] [Abstract][Full Text] [Related]
11. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
12. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Kowall B; Stang A; Rathmann W; Kostev K
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
[TBL] [Abstract][Full Text] [Related]
13. Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: national cohort study.
Dulskas A; Patasius A; Linkeviciute-Ulinskiene D; Zabuliene L; Urbonas V; Smailyte G
Eur J Cancer Prev; 2020 Jul; 29(4):289-293. PubMed ID: 31567536
[TBL] [Abstract][Full Text] [Related]
14. [Metformin, an antidiabetic molecule with anti-cancer properties].
Beck E; Scheen AJ
Rev Med Liege; 2013 Sep; 68(9):444-9. PubMed ID: 24180199
[TBL] [Abstract][Full Text] [Related]
15. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
[TBL] [Abstract][Full Text] [Related]
16. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
[TBL] [Abstract][Full Text] [Related]
17. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes.
Tseng CH
Acta Diabetol; 2014 Apr; 51(2):295-303. PubMed ID: 24509842
[TBL] [Abstract][Full Text] [Related]
18. Impact of metformin on metastases in patients with breast cancer and type 2 diabetes.
Jacob L; Kostev K; Rathmann W; Kalder M
J Diabetes Complications; 2016 Aug; 30(6):1056-9. PubMed ID: 27130560
[TBL] [Abstract][Full Text] [Related]
19. Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study.
Mor A; Petersen I; Sørensen HT; Thomsen RW
BMJ Open; 2016 Aug; 6(8):e011523. PubMed ID: 27543589
[TBL] [Abstract][Full Text] [Related]
20. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
